Illumina Ventures, an independently managed venture fund, led a $484m Series E round for Ginkgo Bioworks, an American biotech company, with participation from General Atlantic and Viking Global Investors. "As programmers of DNA, we recognize rapid pandemic response as an essential technology that must be built alongside biological engineering. The infrastructure we are building for next-generation sequencing is critical for responding to the current pandemic, as well as providing early detection and response for the future," Jason Kelly, Ginkgo Bioworks CEO.